| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): | □ | 研究
| [継承] |
| ○共著種別 (推奨): | □ | 徳島大学以外での研究機関内共著 (徳島大学以外での研究機関内での共同研究)
| [継承] |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | (英) Zhang Yunpeng (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | (英) Yonezawa Atsushi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | (英) Nakagawa Shunsaku (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | (英) Imai Satoshi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 5. | 傳田 将也 ([徳島大学.大学院医歯薬学研究部.薬学域.先端薬学教育研究プロジェクト]/[徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.創薬科学系.機能分子合成薬学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 6. | (英) Omura Tomohiro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 7. | (英) Nakagawa Takayuki (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | (英) Matsubara Kazuo (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) (日) The clinical use of cisplatin is limited by its adverse events, particularly serious nephrotoxicity. It was clarified that cisplatin is transported by a kidney-specific organic cation transporter (OCT2). OCT2 also mediates the uptake of oxaliplatin into renal proximal tubular cells; however, this agent does not lead nephrotoxicity. In the present study, we carried out comparative experiments with cisplatin and oxaliplatin using porcine kidney LLC-PK1 cell monolayers. In the fluorescein-labeled isothiocyanate-dextran flux assay, the basolateral application of cisplatin, but not oxaliplatin, resulted in an increase in the paracellular permeability of cell monolayers. Even though the cellular accumulation of platinum at 50 μM oxaliplatin could reach the same level at 30 μM cisplatin, oxaliplatin did not induce hyper-permeability in cell monolayers. Cisplatin, but not oxaliplatin, significantly activated PKC. In addition, the combination of PKC inhibitors recovered the increase in paracellular permeability. In conclusion, pharmacodynamic mechanisms via PKC could explain the difference in nephrotoxicity between cisplatin and oxaliplatin.
| [継承] |
| ○キーワード (推奨): |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | Drug Metabolism and Pharmacokinetics (日本薬物動態学会)
(pISSN: 1347-4367, eISSN: 1880-0920)
| ○ISSN (任意): | □ | 1880-0920
ISSN: 1347-4367
(pISSN: 1347-4367, eISSN: 1880-0920) Title: Drug metabolism and pharmacokineticsTitle(ISO): Drug Metab PharmacokinetSupplier: 日本薬物動態学会Publisher: Elsevier Limited (NLM Catalog)
(医中誌Web)
(J-STAGE)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 35
| [継承] |
| ○号 (必須): | □ | 1
| [継承] |
| ○頁 (必須): | □ | 111 116
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2019年 9月 18日 (令和 元年 9月 18日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1016/j.dmpk.2019.09.001 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 31964622 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): | □ | 2-s2.0-85077914257
| [継承] |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) PublicationType: Journal Article (日)
| [継承] |